Home › Funds › Soleus Capital Management, L.P. › KNSA
Soleus Capital Management, L.P. position in KNSA
KINIKSA PHARMACEUTICALS INTL · Health Care
Soleus Capital Management, L.P. reported holding 218,958 shares of KNSA (KINIKSA PHARMACEUTICALS INTL) in its Q3 2026 13F filing — a position valued at US$16.3M, representing 0.58% of its reported portfolio and ranking #41 among its reported holdings. Soleus Capital Management, L.P. has disclosed KNSA holdings in 10 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Soleus Capital Management, L.P.'s KNSA position evolved
Soleus Capital Management, L.P. first disclosed a stake in KNSA in Q3 2023 at 157,349 shares (US$2.7M). The position peaked in Q1 2026 at 521,353 shares, worth US$25.1M. Across 10 filings, Soleus Capital Management, L.P. increased the stake 2 time(s), trimmed it 5 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 218,958 shares valued at US$16.3M — a reduction of -27,395 shares quarter over quarter.. Notable position changes include a 51% increase in Q3 2024 (shares fell 21% over the following quarter), a 291% increase in Q4 2025 (shares rose 17% over the following quarter), a 53% trim in Q2 2026 (shares rose 17% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 157.35K | $2.73M | New |
| Q2 2024 | 200.00K | $3.73M | New |
| Q3 2024 | 302.50K | $7.56M | Add |
| Q1 2025 | 469.50K | $10.43M | New |
| Q2 2025 | 254.69K | $7.05M | Reduce |
| Q3 2025 | 150.00K | $5.82M | Reduce |
| Q4 2025 | 587.00K | $24.21M | Add |
| Q1 2026 | 521.35K | $25.10M | Reduce |
| Q2 2026 | 246.35K | $15.75M | Reduce |
| Q3 2026 | 218.96K | $16.34M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About KNSA and 13F data
KNSA (KINIKSA PHARMACEUTICALS INTL) is a Health Care company. 48 other funds we track also report a position in KNSA — the largest reported positions include BAKER BROS. ADVISORS LP (US$211.5M), Rubric Capital Management LP (US$209.9M), TANG CAPITAL MANAGEMENT LLC (US$168.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding KNSA
- BAKER BROS. ADVISORS LP 2.83M sh · $211.49M · Q3 2026
- Rubric Capital Management LP 2.81M sh · $209.91M · Q3 2026
- TANG CAPITAL MANAGEMENT LLC 2.26M sh · $168.61M · Q3 2026
- Spruce Street Capital LP 918.07K sh · $68.50M · Q3 2026
- RICE HALL JAMES & ASSOCIATES, LLC 466.05K sh · $34.77M · Q3 2026
- OBERWEIS ASSET MANAGEMENT INC/ 410.91K sh · $30.66M · Q3 2026
- Penn Capital Management Company, LLC 347.66K sh · $25.97M · Q3 2026
- ESSEX INVESTMENT MANAGEMENT CO LLC 202.02K sh · $15.07M · Q3 2026
More on Soleus Capital Management, L.P.
FAQ
How long has Soleus Capital Management, L.P. held KNSA?
Soleus Capital Management, L.P. has disclosed KNSA holdings in 10 of the last 13 reported quarters, going back to Q3 2023.
What is Soleus Capital Management, L.P.'s current position in KNSA?
As of Q3 2026, Soleus Capital Management, L.P. holds 218.96K shares of KNSA (KINIKSA PHARMACEUTICALS INTL), valued at $16.34M, representing 0.58% of its reported portfolio and ranking #41.
Has Soleus Capital Management, L.P. been buying or selling KNSA?
In the latest 13F filing (Q3 2026), Soleus Capital Management, L.P. reduced its position in KNSA. The position peaked in Q1 2026 at 521.35K shares.
Which other funds hold KNSA?
Other major institutional holders of KNSA include BAKER BROS. ADVISORS LP, Rubric Capital Management LP, TANG CAPITAL MANAGEMENT LLC, among 48 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.